Business Context and Reporting Period
This Form 8-K, dated May 27, 2022, reports that TherapeuticsMD, Inc. (TXMD) entered into a definitive Agreement and Plan of Merger with Athene Parent, Inc. (Parent), an affiliate of EW Healthcare Partners. The transaction involves a cash tender offer followed by a merger, under which TherapeuticsMD will become a wholly-owned subsidiary of Parent.
Key Financial Metrics and Transaction Terms
- Offer Price: $10.00 per share in cash.
- Equity Commitment: EW Healthcare Partners Fund 2, L.P. committed up to approximately $93,000,000 to fund the transaction.
- Termination Fee: $3,250,000 payable by the Company under specific conditions (e.g., superior proposal, change in recommendation).
- Financing Amendment Fee: A paid-in-kind (PIK) fee of $1,780,000 was added to the principal of existing loans under Amendment No. 10.
- Liquidity Covenant: A minimum cash covenant of $10,000,000 was established under Amendment No. 10.
- Debt Status: Interest payments on the existing Financing Agreement were paused; principal and accrued interest are due upon prepayment or maturity.
Material Changes and Agreements
The filing details significant changes to the Company's capital structure and debt obligations effective May 27, 2022:
- Merger Structure: Merger Sub will acquire all outstanding common stock via a tender offer. Following the offer, Merger Sub will merge with the Company. No stockholder vote is required for the merger under Nevada law.
- Debt Restructuring:
- Amendment No. 10: Paused interest payments, extended the maturity date to July 13, 2022, and added the termination of the Merger Agreement as an event of default.
- Amendment No. 11: Contingent on the Merger closing, this amendment requires the payment of all accrued interest and fees in cash and the pledge of 100% of the Company's capital stock by Parent.
- Equity Compensation: All unvested options will vest and be cancelled without consideration. Unvested restricted stock units (RSUs) will vest and convert to cash at the Offer Price. Performance-based units will convert to cash based on target vesting levels.
- ESPP Termination: The 2020 Employee Stock Purchase Plan will be terminated immediately prior to the Effective Time, with the current purchase period ending November 14, 2022, or earlier if the deal closes.
Outlook, Risks, and Contingencies
Management has unanimously recommended the transaction to stockholders. However, the filing highlights several critical risks and contingencies:
- Closing Conditions: The transaction requires at least a majority of voting power to be tendered and the absence of a Material Adverse Effect. The Offer must commence by June 6, 2022.
- Termination Date: The Merger Agreement must be consummated by July 13, 2022, or it may be terminated.
- Going Concern Risk: If the transaction does not close by July 13, 2022, or if the Company fails to meet the $10,000,000 minimum cash covenant, it will constitute an event of default under the Financing Agreement, potentially threatening the Company's ability to continue as a going concern.
- Forward-Looking Statements: Risks include regulatory approval, disruption of operations, employee retention, and the possibility of competing offers.
Investor Verification Checklist
- Verify the commencement date of the cash tender offer (expected by June 6, 2022).
- Confirm the Company's ability to maintain the $10,000,000 minimum cash covenant if the deal is delayed or terminated.
- Review the full text of the Merger Agreement (Exhibit 2.1) and Financing Agreement Amendments (Exhibits 10.1 and 10.2) for detailed covenants and default triggers.
- Monitor the Schedule TO (Tender Offer Statement) and Schedule 14D-9 (Recommendation Statement) once filed with the SEC for final offer terms.
- Assess the impact of the July 13, 2022, termination deadline on the Company's liquidity and debt obligations.